Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Identifieur interne : 000120 ( Main/Exploration ); précédent : 000119; suivant : 000121Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Auteurs : Stephen J. Luen [Australie] ; Roberto Salgado [Belgique] ; Stephen Fox [Australie] ; Peter Savas [Australie] ; Jennifer Eng-Wong [États-Unis] ; Emma Clark [Royaume-Uni] ; Astrid Kiermaier [Suisse] ; Sandra M. Swain [États-Unis] ; Jose Baselga [États-Unis] ; Stefan Michiels [France] ; Sherene Loi [Australie]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2017.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Femelle, Humains, Invasion tumorale, Jeune adulte, Lymphocytes TIL (anatomopathologie), Lymphocytes TIL (immunologie), Marqueurs biologiques tumoraux (métabolisme), Métastase lymphatique, Méthode en double aveugle, Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Récepteur ErbB-2 (métabolisme), Stade de la tumeur, Sujet âgé, Taux de survie, Taxoïdes (administration et posologie), Trastuzumab (administration et posologie), Tumeurs du sein (anatomopathologie), Tumeurs du sein (immunologie), Tumeurs du sein (métabolisme), Tumeurs du sein (traitement médicamenteux), Études de suivi, Études rétrospectives.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Taxoïdes, Trastuzumab.
- anatomopathologie : Lymphocytes TIL, Tumeurs du sein.
- immunologie : Lymphocytes TIL, Tumeurs du sein.
- métabolisme : Marqueurs biologiques tumoraux, Récepteur ErbB-2, Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Invasion tumorale, Jeune adulte, Métastase lymphatique, Méthode en double aveugle, Pronostic, Stade de la tumeur, Sujet âgé, Taux de survie, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Tumor (metabolism), Breast Neoplasms (drug therapy), Breast Neoplasms (immunology), Breast Neoplasms (metabolism), Breast Neoplasms (pathology), Double-Blind Method, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Lymphocytes, Tumor-Infiltrating (immunology), Lymphocytes, Tumor-Infiltrating (pathology), Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Receptor, ErbB-2 (metabolism), Retrospective Studies, Survival Rate, Taxoids (administration & dosage), Trastuzumab (administration & dosage), Young Adult.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Taxoids, Trastuzumab.
- chemical , metabolism : Biomarkers, Tumor, Receptor, ErbB-2.
- drug therapy : Breast Neoplasms.
- immunology : Breast Neoplasms, Lymphocytes, Tumor-Infiltrating.
- metabolism : Breast Neoplasms.
- pathology : Breast Neoplasms, Lymphocytes, Tumor-Infiltrating.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adolescent, Adult, Aged, Double-Blind Method, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Young Adult.
Abstract
High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel.
DOI: 10.1016/S1470-2045(16)30631-3
PubMed: 27964843
Affiliations:
- Australie, Belgique, France, Royaume-Uni, Suisse, États-Unis
- Californie, District de Columbia, Région de Bruxelles-Capitale, Victoria (État), État de New York, Île-de-France
- Bruxelles, Melbourne, Orsay
- Université Paris-Sud, Université de Melbourne, Université libre de Bruxelles
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001339
- to stream PubMed, to step Curation: 001317
- to stream PubMed, to step Checkpoint: 001317
- to stream Ncbi, to step Merge: 004025
- to stream Ncbi, to step Curation: 004025
- to stream Ncbi, to step Checkpoint: 004025
- to stream Main, to step Merge: 000115
- to stream Main, to step Curation: 000120
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.</title><author><name sortKey="Luen, Stephen J" sort="Luen, Stephen J" uniqKey="Luen S" first="Stephen J" last="Luen">Stephen J. Luen</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Salgado, Roberto" sort="Salgado, Roberto" uniqKey="Salgado R" first="Roberto" last="Salgado">Roberto Salgado</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Fox, Stephen" sort="Fox, Stephen" uniqKey="Fox S" first="Stephen" last="Fox">Stephen Fox</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Savas, Peter" sort="Savas, Peter" uniqKey="Savas P" first="Peter" last="Savas">Peter Savas</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Eng Wong, Jennifer" sort="Eng Wong, Jennifer" uniqKey="Eng Wong J" first="Jennifer" last="Eng-Wong">Jennifer Eng-Wong</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Clark, Emma" sort="Clark, Emma" uniqKey="Clark E" first="Emma" last="Clark">Emma Clark</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products, Welwyn, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products, Welwyn</wicri:regionArea><wicri:noRegion>Welwyn</wicri:noRegion></affiliation></author><author><name sortKey="Kiermaier, Astrid" sort="Kiermaier, Astrid" uniqKey="Kiermaier A" first="Astrid" last="Kiermaier">Astrid Kiermaier</name><affiliation wicri:level="1"><nlm:affiliation>Oncology Biomarker Development, Roche, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Oncology Biomarker Development, Roche, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Swain, Sandra M" sort="Swain, Sandra M" uniqKey="Swain S" first="Sandra M" last="Swain">Sandra M. Swain</name><affiliation wicri:level="2"><nlm:affiliation>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="Jose" last="Baselga">Jose Baselga</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="4"><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27964843</idno><idno type="pmid">27964843</idno><idno type="doi">10.1016/S1470-2045(16)30631-3</idno><idno type="wicri:Area/PubMed/Corpus">001339</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001339</idno><idno type="wicri:Area/PubMed/Curation">001317</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001317</idno><idno type="wicri:Area/PubMed/Checkpoint">001317</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001317</idno><idno type="wicri:Area/Ncbi/Merge">004025</idno><idno type="wicri:Area/Ncbi/Curation">004025</idno><idno type="wicri:Area/Ncbi/Checkpoint">004025</idno><idno type="wicri:Area/Main/Merge">000115</idno><idno type="wicri:Area/Main/Curation">000120</idno><idno type="wicri:Area/Main/Exploration">000120</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.</title><author><name sortKey="Luen, Stephen J" sort="Luen, Stephen J" uniqKey="Luen S" first="Stephen J" last="Luen">Stephen J. Luen</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Salgado, Roberto" sort="Salgado, Roberto" uniqKey="Salgado R" first="Roberto" last="Salgado">Roberto Salgado</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Pathology, GZA-Hospitals, Antwerp, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region><settlement type="city">Bruxelles</settlement></placeName><orgName type="university">Université libre de Bruxelles</orgName></affiliation></author><author><name sortKey="Fox, Stephen" sort="Fox, Stephen" uniqKey="Fox S" first="Stephen" last="Fox">Stephen Fox</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Savas, Peter" sort="Savas, Peter" uniqKey="Savas P" first="Peter" last="Savas">Peter Savas</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Eng Wong, Jennifer" sort="Eng Wong, Jennifer" uniqKey="Eng Wong J" first="Jennifer" last="Eng-Wong">Jennifer Eng-Wong</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Clark, Emma" sort="Clark, Emma" uniqKey="Clark E" first="Emma" last="Clark">Emma Clark</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products, Welwyn, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products, Welwyn</wicri:regionArea><wicri:noRegion>Welwyn</wicri:noRegion></affiliation></author><author><name sortKey="Kiermaier, Astrid" sort="Kiermaier, Astrid" uniqKey="Kiermaier A" first="Astrid" last="Kiermaier">Astrid Kiermaier</name><affiliation wicri:level="1"><nlm:affiliation>Oncology Biomarker Development, Roche, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Oncology Biomarker Development, Roche, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Swain, Sandra M" sort="Swain, Sandra M" uniqKey="Swain S" first="Sandra M" last="Swain">Sandra M. Swain</name><affiliation wicri:level="2"><nlm:affiliation>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lombardi Comprehensive Cancer Centre, Georgetown University, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="Jose" last="Baselga">Jose Baselga</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="4"><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biomarkers, Tumor (metabolism)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (immunology)</term><term>Breast Neoplasms (metabolism)</term><term>Breast Neoplasms (pathology)</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Lymphocytes, Tumor-Infiltrating (immunology)</term><term>Lymphocytes, Tumor-Infiltrating (pathology)</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Receptor, ErbB-2 (metabolism)</term><term>Retrospective Studies</term><term>Survival Rate</term><term>Taxoids (administration & dosage)</term><term>Trastuzumab (administration & dosage)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Femelle</term><term>Humains</term><term>Invasion tumorale</term><term>Jeune adulte</term><term>Lymphocytes TIL (anatomopathologie)</term><term>Lymphocytes TIL (immunologie)</term><term>Marqueurs biologiques tumoraux (métabolisme)</term><term>Métastase lymphatique</term><term>Méthode en double aveugle</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Récepteur ErbB-2 (métabolisme)</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Taux de survie</term><term>Taxoïdes (administration et posologie)</term><term>Trastuzumab (administration et posologie)</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (immunologie)</term><term>Tumeurs du sein (métabolisme)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Taxoids</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers, Tumor</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Taxoïdes</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Lymphocytes TIL</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes TIL</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Breast Neoplasms</term><term>Lymphocytes, Tumor-Infiltrating</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Récepteur ErbB-2</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term><term>Lymphocytes, Tumor-Infiltrating</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Retrospective Studies</term><term>Survival Rate</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Invasion tumorale</term><term>Jeune adulte</term><term>Métastase lymphatique</term><term>Méthode en double aveugle</term><term>Pronostic</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Taux de survie</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>France</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Californie</li><li>District de Columbia</li><li>Région de Bruxelles-Capitale</li><li>Victoria (État)</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Bruxelles</li><li>Melbourne</li><li>Orsay</li></settlement><orgName><li>Université Paris-Sud</li><li>Université de Melbourne</li><li>Université libre de Bruxelles</li></orgName></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Luen, Stephen J" sort="Luen, Stephen J" uniqKey="Luen S" first="Stephen J" last="Luen">Stephen J. Luen</name></region><name sortKey="Fox, Stephen" sort="Fox, Stephen" uniqKey="Fox S" first="Stephen" last="Fox">Stephen Fox</name><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><name sortKey="Savas, Peter" sort="Savas, Peter" uniqKey="Savas P" first="Peter" last="Savas">Peter Savas</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Salgado, Roberto" sort="Salgado, Roberto" uniqKey="Salgado R" first="Roberto" last="Salgado">Roberto Salgado</name></region></country><country name="États-Unis"><region name="Californie"><name sortKey="Eng Wong, Jennifer" sort="Eng Wong, Jennifer" uniqKey="Eng Wong J" first="Jennifer" last="Eng-Wong">Jennifer Eng-Wong</name></region><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="Jose" last="Baselga">Jose Baselga</name><name sortKey="Swain, Sandra M" sort="Swain, Sandra M" uniqKey="Swain S" first="Sandra M" last="Swain">Sandra M. Swain</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Clark, Emma" sort="Clark, Emma" uniqKey="Clark E" first="Emma" last="Clark">Emma Clark</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Kiermaier, Astrid" sort="Kiermaier, Astrid" uniqKey="Kiermaier A" first="Astrid" last="Kiermaier">Astrid Kiermaier</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000120 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000120 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27964843
|texte= Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27964843" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |